ClinicalTrials.gg

Alopecia Areata clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 220 studies for Alopecia Areata across more than 10 countries. 61 are recruiting or about to start. 202 of them are mainly about Alopecia Areata (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-09.

Status

Completed
93
Recruiting
41
Status unknown
22
Active, not recruiting
19
Terminated
17
Not yet recruiting
15

Phase

Phase 2
70
Phase 3
28
Phase 4
25
Phase 1
21
Early Phase 1
7

Where

United States
98
Egypt
31
Canada
28
China
24
France
19
Japan
18

Who develops what

Add Alopecia Areata to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 11 programs from 11 companies, 10 with this as their studies’ main aim; 3 with a live phase 3 study; 5 primary completions in the next 12 months. Compare AbbVie, Almirall and argenx here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

None given by two companies or more yet.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
ritlecitinibApproved: US 2023 · EU 2023☆ Track4 live phase-3 studies: NCT07029711, NCT07733765, NCT06873945Pfizer
DeuruxolitinibApproved: US 2024☆ Track3 live phase-3 studies: NCT07617597, NCT07133308, NCT03898479Sun Pharmaceutical Industries Limited
upadacitinibApproved: US 2019 · EU 2019☆ Track3 live phase-3 studies: NCT07772492, NCT06012240, NCT07023302AbbVie

The 3 in phase 3 with the nearest primary completion, of 11 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (5)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Nov 2026 est.reproxalap · Aldena Therapeutics · Phase 2 main aimNCT06826196 A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALD-102 Solution in Subjects With Alopecia Areata — primary endpoint: Number of participants with treatment-related adverse effects (AEs) and severe adverse effects (SAEs) as assessed by CTCAE, and injection site reactions (ISRs), evaluated by local tolerability assessments and numerical scales. · 9 enrolled
  • 2 Dec 2026 est.ritlecitinib · Pfizer · Phase 3 main aimNCT07029711 A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata — primary endpoint: For US and Countries Following US Analysis Plan: Response based on achieving an absolute Severity of Alopecia Tool (SALT) score ≤20. · 208 enrolled
  • May 2027 est.Deuruxolitinib · Sun Pharmaceutical Industries Limited · Phase 3 main aimNCT03898479 Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata — primary endpoint: Number of Participants with Adverse Events as a Measure of Safety · 1,000 enrolled

2 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Alopecia Areata studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here JAK inhibitors 10 open · Tyrosine kinase inhibitors (TKIs) 10 open · Corticosteroids 3 open · Antimetabolites 2 open

Coming up

24studies finish main data collection within a year2 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 41 Alopecia Areata studies recruiting now, 16 (39%) set no upper age limit and 21 (51%) stop at 75 or younger. 20 (49%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 5 (12%) take healthy volunteers.

Recruiting studies that take each age, of 41
AgeWomenMen
108 (20%)8 (20%)
1833 (80%)33 (80%)
3034 (83%)34 (83%)
4033 (80%)33 (80%)
5033 (80%)33 (80%)
6531 (76%)31 (76%)
7524 (59%)24 (59%)
8517 (41%)17 (41%)

Across all 220 studies, recruiting or not: 55% stop at 75 or younger and 43% at 65; 36% take children; 0% are for women only and <1% for men only; 17% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Alopecia Areata studies take

Of 30 phase 2 interventional studies under Alopecia Areata, half reached primary completion within 24 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 224 mo15–35 · 30 studies——
Phase 332 mo18–46 · 20 studies——
Interventional, no phase13 mo9–24 · 21 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 220. Browse all 220 → or search them.